Glaukos stock price target raised to $252 by BTIG on revenue outlook
BTIG raised Glaukos (GKOS) price target to $252 from $234, citing strong revenue outlook. GKOS shares are up 118% YTD. The company projected $1B FY2027 revenue, exceeding estimates. Q3 2026 revenue was $211M, up 58% YoY. Several firms raised price targets post-results.
How this was made
The 30-second read
Why it matters
The guidance upgrade is the primary catalyst for a potential price rally.
Market read
Guidance lift and higher target could drive GKOS shares higher in the short term.
What to watch
Potential regulatory delays for new products could temper upside.
Background
The article recaps analyst price‑target upgrades and Glaukos' FY2027 revenue guidance after its Q3 2026 results.
Ticker impact
BTIG raised its price target to $252 and Glaukos issued FY2027 revenue guidance of ~$1B, up from prior estimates.
likely upward pressure as investors price in higher revenue expectations
The new $1B revenue outlook and higher target represent a material shift from prior guidance, prompting buying interest.
Market effects
Positive for the ophthalmic medical device sector as Glaukos' guidance may lift peers.
U.S. biotech and med‑tech stocks could see modest gains.
Limited to investors tracking eye‑care device manufacturers.
Counterpoint
If execution risks on Epioxa and iDose materialize, the guidance may be overly optimistic.
Key entities
- companyGlaukos Corporation
Medical technology firm specializing in glaucoma treatments.
- analystBTIG
Equity research firm raising price target.



